Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
68.51
+0.81 (1.20%)
At close: Jun 27, 2025, 4:00 PM
68.45
-0.06 (-0.09%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
6.94
Revenue / Employee
3,919,133 DKK
Employees
77,349
Market Cap
304.96B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
NVO News
- 1 day ago - Health Rounds: Novo Nordisk's semaglutide may help some with type 1 diabetes - Reuters
- 2 days ago - Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership - WSJ
- 2 days ago - Novo Nordisk ties up with WeightWatchers to sell Wegovy - Reuters
- 2 days ago - Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety - PRNewsWire
- 3 days ago - Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy - Reuters
- 3 days ago - Weight loss and diabetes jabs linked to potentially fatal side effect - Skynews
- 3 days ago - NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm - Business Wire
- 3 days ago - The Best European Stocks to Buy - Kiplinger